Benitec Biopharma Inc. (BNTC)
Chart Events
Performance Outlook
| Previous Close | 3.6500 |
| Open | 3.6800 |
| Bid | 3.4500 x 1000 |
| Ask | 3.6400 x 3100 |
| Day's Range | 3.4800 - 3.7000 |
| 52 Week Range | 2.5200 - 17.4150 |
| Volume | 144,923 |
| Avg. Volume | 497,032 |
| Market Cap | 15.639M |
| Beta (5Y Monthly) | 1.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -9.0860 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
Benitec Biopharma Announces 2020 Annual Stockholder Meeting
Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at 3 p.m. (Pacific Time). The meeting details and instructions on how to access the virtual meeting are provided below:
- Simply Wall St.
A Quick Analysis On Benitec Biopharma's (NASDAQ:BNTC) CEO Compensation
Jerel Banks became the CEO of Benitec Biopharma Inc. ( NASDAQ:BNTC ) in 2018, and we think it's a good time to look at...
- PR Newswire
Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Purchase Additional Shares
Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced the closing of an underwritten public offering of 3,225,806 shares of its common stock (or common stock equivalents in lieu thereof) at an effective offering price of $3.10 per share of common stock. In addition, the Company also announced that the underwriter fully exercised its over-allotment option to purchase 483,870 additional shares of its common stock.
